Lupus Nephritis

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 25, 2021.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 11, 2021.

In this Q&A, corresponding author Richard A Furie, MD, discussed the findings of his study comparing obinutuzumab with placebo for the treatment of proliferative lupus nephritis in combination with standard therapies.

“Although many different autoantibodies have been investigated in SLE, only a limited number of autoantibodies are being used in clinical practice,” investigators stated. “Due to these limitations, there has been great interest in the discovery of new autoantibodies that can be used in clinical practice.”

Neil Solomons, MD, sits down to discuss his latest study, entitled “Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet,” which will be presented at EULAR 2021.

Voclosporin (LUPKYNIS), in combination with an existing immunosuppressive therapy regimen, works to safely and effectively treat adult patients with lupus nephritis.

The approval was based on findings from the Belimumab International Study in Lupus Nephritis (BLISS-LN) study.

At this year's annual meeting of the American College of Rheumatology, there were a number of studies presented on different treatments for lupus. It's an exciting time in lupus research says Dr. Richard Furie, chief of rheumatology at Northwell Health in New York. In today's one on one interview, he breaks down some of the lupus studies presented at the meeting

Welcome to Overdrive, the podcast from Rheumatology Network. This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis, the impact of COVID-19 on rheumatic disease patients, and pregnancy outcomes in ILD patients. Today, Dr. Fotios Koumpouras of the Yale School of Medicine, highlights some studies you won't want to miss at this year's meeting.

Anti-inflammatory and immunosuppressive agents are the two primary classes of drugs used to treat lupus nephritis. Now, a new study shows that the addition of the monoclonal antibody belimumab to standard therapy may make a meaningful difference in this hard-to-treat patient population.

A possible new treatment for advanced lupus nephritis passes a phase two trial, according to a study presented at Kidney Week, the annual meeting of the American Society for Nephrology. The treatment, a CD20 antagonist called obinutuzumab, led to improvements in 41 percent of patients with lupus nephritis—a condition that affects one in 60 people with systemic lupus.

Treatments for lupus nephritis can cost patients over $50,000 a year, according to a study presented yesterday at the American Society of Nephrology Kidney Week annual meeting.

Belimumab (Benlysta, GlaxoSmithKline) can improve the kidney health of people with lupus nephritis, a new phase 3 clinical trial suggests.

Today, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

Simultaneous use of more than one drug is gaining traction as a treatment strategy for severe lupus symptoms, particularly in people with chronic kidney disease.

In this slideshow, we highlight some presentations from EULAR 2020 we thought would interest you. The list includes a study that shows primary Sjogren’s syndrome affects men as well, and it highlights findings from a study that shows voclosporin was effective in treating lupus neprhitis in Latinas, a group disproportionately affected by the condition. More in this slideshow.

Dr. Gregg Silverman said identification of Ruminococcus gnavus could allow earlier diagnosis of lupus nephritis.

Outcomes for patients with lupus nephritis, which can lead to irreversible renal impairment, can be improved with better measures to evaluate risk and detect early disease, along with new treatments, say researchers writing in Nature Reviews Rheumatology.

In a new study, investigators show belimumab as a treatment could normalize or stabilize proteinuria is patients with lupus nephritis.

Richard Furie, MD, chief of the division of rheumatology with Norwell Health, discusses the results of a phase 2 trial examining obinutuzumab for lupus nephritis.

Roche announced this week that the U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, a major morbidity of systemic lupus erythematosus (SLE).

Investigators are currently pursuing at least 50 possible new treatments, or treatment targets, for systemic lupus and lupus nephritis. We're tracking the studies and in this slideshow, we highlight the results from nine new studies on lupus nephritis.

Patients with systemic lupus erythematosus (SLE) are at an increased risk for fractures, new research shows. The risk is particularly high among patients with lupus nephritis.

Lupus nephritis remained in remission for over 10 years in a group of patients who were treated with cyclosporine A, mycophenolate mofetil or azathioprine, shows a study presented at the European Congress of Rheumatology (EULAR) annual meeting this weekend in Madrid.